Skip to content
AnalystLens

Colgate-Palmolive 8-K Report, Financial Results (Jan 31, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed January 31, 2025
Period End
January 31, 2025
Security
CL
In the record · 2016–202610-K1210-Q338-K102

CL filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 102 current reports (8-K) between 2016 and 2026.

  1. Restructuring8-K · Oct ’17Oct ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Leadership change8-K · Jun ’22Jun ’22
  4. Restructuring8-K · May ’26May ’26

01—Abstract

Summary

Summary of the 8-K filed January 31, 2025. Cited figures are marked; the original filing is the authoritative source.

Colgate-Palmolive reported fourth quarter and full year 2024 results on January 31, 2025, marking its first year with net sales above $20 billiona ($20,101M, up 3.3% GAAP).

Organic sales grew a strong 7.4% for the full year, the sixth consecutive year at or above the company's 3%-5% target, with growth in every division and all four categories. The gap between the 3.3% reported and 7.4% organic growth reflects a 4.1% foreign exchange headwind. Profitability improved markedly: GAAP gross margin expanded 230 basis points to 60.5%, GAAP diluted EPS rose 27% to $3.51b, and Base Business (non-GAAP) EPS rose 11% to $3.60.

Operating leverage and a 15% increase in advertising spending ($2,720Mc) were key features of the year. Fourth quarter results were softer at the top line: net sales were flat (-0.1%) and organic sales rose 4.3%, with Latin America (-7.2% reported, heavily hit by a 16.4% FX drag) and North America (-1.0% reported, -0.7% organic) the weakest areas. Volume growth of 2.5% and pricing of 1.8% drove organic growth.

Hill's Pet Nutrition was the standout, with operating profit up 19% and margin expanding 340 basis points, while North America operating profit fell 11%. Quarterly GAAP EPS rose 3% to $0.90d and Base Business EPS rose 5% to $0.91. For 2025, management guided to roughly flat net sales including a mid-single-digit FX headwind, organic growth within its 3%-5% target (net of the planned exit from private label pet nutrition), gross margin expansion, flat to slightly higher advertising, and low-to-mid single-digit Base Business EPS growth (mid-single-digit on a GAAP basis).

Guidance is based on current spot rates. Management also cited tariffs, geopolitical tensions, and currency as risks to the outlook. Free cash flow before dividends rose to $3.5 billion, and the company returned $3.4 billion to shareholders through dividends and buybacks.

02—Key points

Key Highlights

  1. Full-year net sales surpassed $20 billion for the first time, reaching $20,101M (+3.3% reported), while organic sales grew 7.4%.
  2. GAAP diluted EPS rose 27% to $3.51; Base Business (non-GAAP) EPS rose 11% to $3.60, with gross margin expanding 230 bps to 60.5% (GAAP).
  3. Fourth-quarter net sales were flat at $4,944M (-0.1%), but organic sales grew 4.3% on 2.5% volume and 1.8% pricing; FX was a 4.4% headwind.
  4. Hill's Pet Nutrition delivered strong Q4 operating profit growth of 19% and a 340 bps margin expansion, while North America operating profit fell 11%.
  5. 2025 guidance: roughly flat net sales (mid-single-digit FX headwind), organic growth in the 3%-5% range, and low-to-mid single-digit Base Business EPS growth.
  6. Cash generation remained robust: operating cash flow rose 10% to $4.1B and free cash flow before dividends reached $3.5B; $3.4B returned to shareholders.
  7. Total debt declined to $7.9B from $8.5B, and debt less cash fell to $6.7B from $7.4B, improving the balance sheet.

03—Questions

Frequently Asked Questions

  1. Why is there such a large gap between reported sales growth (3.3%) and organic growth (7.4%) for 2024?

    Organic sales exclude foreign exchange, acquisitions and divestitures. Full-year FX reduced reported net sales growth by about 4.1 percentage points, largely due to weakness in emerging-market currencies such as the Latin American and African/Eurasian currencies, so underlying demand was considerably stronger than the headline figure suggests.

  2. What drove the margin improvement in 2024?

    Gross profit margin rose 230 bps to 60.5% on a GAAP basis, supported by pricing, productivity initiatives and favorable mix. Operating margin expanded 70 bps to 21.2% (GAAP). Despite a 15% increase in advertising spending and a rise in SG&A, operating leverage from strong sales growth and lower non-service postretirement costs (down from $360M to $87M, mostly due to the prior-year ERISA charge) boosted EPS.

  3. Why was fourth-quarter performance weaker than the full year?

    Reported Q4 net sales were flat (-0.1%), mainly because of a 4.4% FX headwind, particularly in Latin America (-16.4% FX). North America also declined on lower pricing and volume, and its operating profit fell 11%. Hill's and Asia Pacific were positives, and organic growth of 4.3% remained healthy.

  4. What is the outlook for 2025 and what are the key risks?

    Colgate guided to roughly flat net sales, including a mid-single-digit FX headwind at current spot rates. Organic growth is expected within its 3%-5% long-term target, net of the planned exit from private label pet nutrition. Base Business EPS is expected to grow low-to-mid single digits. Key risks include new tariffs, the conflicts in Ukraine and the Middle East, China-Taiwan tensions, currency volatility and tax or interest rate changes.

  5. How is Colgate allocating its cash?

    In 2024 the company generated $4.1B in operating cash flow and $3.5B in free cash flow before dividends. It paid $1.8B in dividends and repurchased $1.7B of stock, funded partly by $638M in proceeds from option exercises. Total debt was reduced by roughly $600M to $7.9B, and the company continued to invest in advertising and capabilities.

04—Continue

← View all 8-K filings